NCT06172309View on ClinicalTrials.gov

A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

April 20, 2024

Study Completion Date

May 27, 2024

Conditions
Advanced Solid Tumors
Interventions
DRUG

NTQ1062

tablet(s) PO

Trial Locations (2)

200120

Shanghai East hospital, Shanghai

250000

Shandong Cancer Hospital, Jinan

Sponsors
All Listed Sponsors
lead

Nanjing Chia-tai Tianqing Pharmaceutical

INDUSTRY